@ardamanshergill.bsky.social
Reposted
‼️ #ASCO25 #JCOOA simultaneous publication by O'Neill et al:
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social
June 2, 2025 at 8:06 PM
‼️ #ASCO25 #JCOOA simultaneous publication by O'Neill et al:
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social
Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social
Reposted
#ASCO25 #OncSky #crcsm
NEW: Randomized trial of exercise vs health ed in people w/ #ColonCancer after adjuvant chemo: disease-free (HR 0.72; 6.4% abs diff at 5y) & overall (HR 0.63; 7.1% abs diff at 8y) survival improved w/ exercise! NNT ~14. ACTUALLY tolerable. 🏆
www.nejm.org/doi/full/10....
NEW: Randomized trial of exercise vs health ed in people w/ #ColonCancer after adjuvant chemo: disease-free (HR 0.72; 6.4% abs diff at 5y) & overall (HR 0.63; 7.1% abs diff at 8y) survival improved w/ exercise! NNT ~14. ACTUALLY tolerable. 🏆
www.nejm.org/doi/full/10....
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | NEJM
Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, ...
www.nejm.org
June 1, 2025 at 4:12 PM
#ASCO25 #OncSky #crcsm
NEW: Randomized trial of exercise vs health ed in people w/ #ColonCancer after adjuvant chemo: disease-free (HR 0.72; 6.4% abs diff at 5y) & overall (HR 0.63; 7.1% abs diff at 8y) survival improved w/ exercise! NNT ~14. ACTUALLY tolerable. 🏆
www.nejm.org/doi/full/10....
NEW: Randomized trial of exercise vs health ed in people w/ #ColonCancer after adjuvant chemo: disease-free (HR 0.72; 6.4% abs diff at 5y) & overall (HR 0.63; 7.1% abs diff at 8y) survival improved w/ exercise! NNT ~14. ACTUALLY tolerable. 🏆
www.nejm.org/doi/full/10....
Reposted
So grateful to have worked with this amazing group of friends and colleagues on #research priorities for #systemic therapies for #cholangiocarcinoma #biliarytractcancer #CCA #BTC @cholangiocarcinoma.bsky.social #HUNIMED #HUMANITAS @rachnatshroff.bsky.social @ardamanshergill.bsky.social
April 11, 2025 at 2:22 AM
So grateful to have worked with this amazing group of friends and colleagues on #research priorities for #systemic therapies for #cholangiocarcinoma #biliarytractcancer #CCA #BTC @cholangiocarcinoma.bsky.social #HUNIMED #HUMANITAS @rachnatshroff.bsky.social @ardamanshergill.bsky.social
Reposted
Join Eileen O'Reilly today at #GI25 to learn about new therapeutic explorations into bispecific antibodies and checkpoint inhibitors for #pancreaticcancer. #pancsm @mskcancercenter.bsky.social @ascocancer.bsky.social
bit.ly/4jro4ZF
10:50 a.m. – 11 a.m. PST | Level 2, Ballroom
bit.ly/4jro4ZF
10:50 a.m. – 11 a.m. PST | Level 2, Ballroom
January 24, 2025 at 5:01 PM
Join Eileen O'Reilly today at #GI25 to learn about new therapeutic explorations into bispecific antibodies and checkpoint inhibitors for #pancreaticcancer. #pancsm @mskcancercenter.bsky.social @ascocancer.bsky.social
bit.ly/4jro4ZF
10:50 a.m. – 11 a.m. PST | Level 2, Ballroom
bit.ly/4jro4ZF
10:50 a.m. – 11 a.m. PST | Level 2, Ballroom
Reposted
Dr. Vincent Picozzi is enthusiastic about the results of the PANOVA-3 trial, which uses an electricity-based technique to kill cancer cells. bit.ly/40xGxeh
#PancreaticCancer #CancerSky #OncoSky #ClincalTrials
#PancreaticCancer #CancerSky #OncoSky #ClincalTrials
Electricity-Based Treatment Boosts Overall Survival
Dr. Vincent Picozzi is enthusiastic about the results of the PANOVA-3 trial, which uses an electricity-based technique to kill cancer cells.
bit.ly
January 28, 2025 at 10:49 PM
Dr. Vincent Picozzi is enthusiastic about the results of the PANOVA-3 trial, which uses an electricity-based technique to kill cancer cells. bit.ly/40xGxeh
#PancreaticCancer #CancerSky #OncoSky #ClincalTrials
#PancreaticCancer #CancerSky #OncoSky #ClincalTrials
Reposted
Pamrevlumab + chemo fails to improve OS and PFS in locally advanced pancreatic cancer, H/T: @lgoodbu.bsky.social
January 29, 2025 at 7:09 PM
Pamrevlumab + chemo fails to improve OS and PFS in locally advanced pancreatic cancer, H/T: @lgoodbu.bsky.social
Reposted
An advisory from the US Surgeon General highlights the link between alcohol consumption and #cancer, and calls for updated warning labels and more provider and patient education.
More coverage here: conexiant.com/family-medic...
The full advisory can be found here: www.hhs.gov/sites/defaul...
More coverage here: conexiant.com/family-medic...
The full advisory can be found here: www.hhs.gov/sites/defaul...
Surgeon General Issues Advisory on Alcohol, Cancer Link
Of all breast cancer cases in the U.S., 16.4% are directly linked to alcohol consumption.
conexiant.com
January 3, 2025 at 5:49 PM
An advisory from the US Surgeon General highlights the link between alcohol consumption and #cancer, and calls for updated warning labels and more provider and patient education.
More coverage here: conexiant.com/family-medic...
The full advisory can be found here: www.hhs.gov/sites/defaul...
More coverage here: conexiant.com/family-medic...
The full advisory can be found here: www.hhs.gov/sites/defaul...
Reposted
Scott Kopetz, MD, PhD, of @MDAndersonNews, reviews the BREAKWATER study on encorafenib + cetuximab ± chemotherapy for BRAF V600E–mutant metastatic colorectal cancer at ASCO GI 2025. #BreastCancer #Oncology ascopost.com/videos/2024-...
January 28, 2025 at 8:21 PM
Scott Kopetz, MD, PhD, of @MDAndersonNews, reviews the BREAKWATER study on encorafenib + cetuximab ± chemotherapy for BRAF V600E–mutant metastatic colorectal cancer at ASCO GI 2025. #BreastCancer #Oncology ascopost.com/videos/2024-...